Sun Pharmaceutical Industries Ltd begins the integration of its Opiates business in Australia following the successful completion of this acquisition from GKS. This acquisition fortifies Sun Pharma's global position with two Opiates manufacturing facilities in Port Fairy and Latrobe complementing its current API manufacturing footprint globally.
Sun Pharma now offers a rich basket of Opiates product line in addition to a large API portfolio and dosage formulations covering a broad range chronic and acute prescription drugs. The acquisition also brings a specialized team to drive business growth.
The Opiates acquisition allow Sun Pharma to:
- Significantly expands its narcotic raw material market share
- Enhance Opiate Alkaloids portfolio and depth in Global opiates market
- Strengthen its strategic position in the global opiates business